Is Evolent Health Stock a Good Investment?
Evolent Health Investment Advice | EVH |
- Examine Evolent Health's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Evolent Health's leadership team and their track record. Good management can help Evolent Health navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Technology space and any emerging trends that could impact Evolent Health's business and its evolving consumer preferences.
- Compare Evolent Health's performance and market position to its competitors. Analyze how Evolent Health is positioned in terms of product offerings, innovation, and market share.
- Check if Evolent Health pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Evolent Health's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Evolent Health stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Evolent Health is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Evolent Health Stock
Researching Evolent Health's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 96.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.25. Some equities with similar Price to Book (P/B) outperform the market in the long run. Evolent Health recorded a loss per share of 0.92. The entity had not issued any dividends in recent years.
To determine if Evolent Health is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Evolent Health's research are outlined below:
| Evolent Health generated a negative expected return over the last 90 days | |
| Evolent Health has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 1.96 B. Reported Net Loss for the year was (113.04 M) with profit before taxes, overhead, and interest of 316.58 M. | |
| Evolent Health has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Evolent Health, Inc. This Small-Cap Stock Is Ready To Explode |
Evolent Health Quarterly Good Will |
|
Evolent Health uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Evolent Health. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evolent Health's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Evolent Health's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Evolent Health's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-05 | 2020-09-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2018-08-07 | 2018-06-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2021-08-04 | 2021-06-30 | -0.04 | -0.02 | 0.02 | 50 | ||
2017-05-09 | 2017-03-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2017-02-28 | 2016-12-31 | -0.2 | -0.18 | 0.02 | 10 | ||
2016-11-09 | 2016-09-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2023-08-02 | 2023-06-30 | 0.11 | 0.14 | 0.03 | 27 | ||
2020-02-25 | 2019-12-31 | -0.04 | -0.07 | -0.03 | 75 |
Know Evolent Health's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evolent Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evolent Health backward and forwards among themselves. Evolent Health's institutional investor refers to the entity that pools money to purchase Evolent Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 2.7 M | Bellevue Group Ag | 2024-09-30 | 2.7 M | Orbimed Advisors, Llc | 2024-06-30 | 2.6 M | Blair William & Co | 2024-06-30 | 2.6 M | Geode Capital Management, Llc | 2024-09-30 | 2.5 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.4 M | First Light Asset Management, Llc | 2024-09-30 | 2.3 M | Bank Of New York Mellon Corp | 2024-06-30 | 2 M | Holocene Advisors, Lp | 2024-09-30 | 2 M | Wellington Management Company Llp | 2024-06-30 | 11.2 M | Vanguard Group Inc | 2024-09-30 | 10.9 M |
Evolent Health's market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.29 B.Market Cap |
|
Evolent Health's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.04) | (0.04) | |
| Return On Assets | (0.04) | (0.04) | |
| Return On Equity | (0.11) | (0.10) |
Determining Evolent Health's profitability involves analyzing its financial statements and using various financial metrics to determine if Evolent Health is a good buy. For example, gross profit margin measures Evolent Health's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Evolent Health's profitability and make more informed investment decisions.
Evaluate Evolent Health's management efficiency
The current Return On Tangible Assets is estimated to decrease to -0.15. The current Return On Capital Employed is estimated to decrease to -0.04. As of now, Evolent Health's Other Assets are increasing as compared to previous years. The Evolent Health's current Other Current Assets is estimated to increase to about 73.6 M, while Total Current Assets are projected to decrease to under 354.3 M. Evolent Health's management efficiency ratios could be used to measure how well Evolent Health manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.60 | 9.12 | |
| Tangible Book Value Per Share | (7.20) | (6.84) | |
| Enterprise Value Over EBITDA | (166.50) | (158.17) | |
| Price Book Value Ratio | 3.44 | 3.61 | |
| Enterprise Value Multiple | (166.50) | (158.17) | |
| Price Fair Value | 3.44 | 3.61 | |
| Enterprise Value | 749.4 M | 742.8 M |
The leadership approach at Evolent Health's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 1.587 |
Basic technical analysis of Evolent Stock
As of the 25th of November, Evolent Health shows the Standard Deviation of 6.47, variance of 41.92, and Mean Deviation of 3.11. Evolent Health technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Evolent Health's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evolent Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evolent Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evolent Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Evolent Health's Outstanding Corporate Bonds
Evolent Health issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Evolent Health uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Evolent bonds can be classified according to their maturity, which is the date when Evolent Health has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Understand Evolent Health's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Evolent Health's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (1.21) | |||
| Mean Deviation | 3.11 | |||
| Coefficient Of Variation | (498.43) | |||
| Standard Deviation | 6.47 | |||
| Variance | 41.92 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (1.44) | |||
| Total Risk Alpha | (2.33) | |||
| Treynor Ratio | (1.22) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (5.92) | |||
| Potential Upside | 4.48 | |||
| Skewness | (4.92) | |||
| Kurtosis | 34.56 |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (1.21) | |||
| Mean Deviation | 3.11 | |||
| Coefficient Of Variation | (498.43) | |||
| Standard Deviation | 6.47 | |||
| Variance | 41.92 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (1.44) | |||
| Total Risk Alpha | (2.33) | |||
| Treynor Ratio | (1.22) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (5.92) | |||
| Potential Upside | 4.48 | |||
| Skewness | (4.92) | |||
| Kurtosis | 34.56 |
Consider Evolent Health's intraday indicators
Evolent Health intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evolent Health stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Evolent Health Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 26th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Evolent Stock media impact
Far too much social signal, news, headlines, and media speculation about Evolent Health that are available to investors today. That information is available publicly through Evolent media outlets and privately through word of mouth or via Evolent internal channels. However, regardless of the origin, that massive amount of Evolent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Evolent Health news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Evolent Health relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Evolent Health's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Evolent Health alpha.
Evolent Health Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Evolent Health can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Evolent Health Corporate Directors
| Bridget Duffy | Independent Director | Profile | |
| Bruce Felt | Independent Director | Profile | |
| Cheryl Scott | Lead Independent Director | Profile | |
| David Farner | Director | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.92) | Revenue Per Share 21.554 | Quarterly Revenue Growth 0.216 | Return On Assets 0.0073 | Return On Equity (0.06) |
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Evolent Health's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.